Morphotek® Announces Evaluation Agreement with the University Hospital Heidelberg

Date Posted: Thursday, January 15, 2009

Print Email to a friend

Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced the signing of an evaluation agreement with the University Hospital Heidelberg and its Technology Transfer Office, Germany to advance the company's efforts in the discovery and development of therapeutic antibodies in oncology.

The agreement provides for a research grant to the University Hospital/National Center for Tumor Diseases (NCT) and for use by Morphotek of biological materials to generate and validate therapeutic monoclonal antibodies to oncology targets selected by Morphotek.

“We are very pleased to be collaborating with one of the world’s leading research and clinical centers in oncology,” said Nicholas Nicolaides, Ph.D., President and CEO of Morphotek.

“This research program offers Morphotek unique clinical materials to generate and validate potential therapeutic antibodies using our MORPHODOMA® technologies and will enable us to advance our goal of discovering and developing novel monoclonal antibody therapeutics. The clinical group at NCT is dedicated to bringing new therapies to treat patients with cancer, and we look forward to collaborating with them to discover new experimental medicines with potential to treat patients with various cancers.”

Further Information: http://www.morphotek.com



Related news from our archive

Morphotek® Announces Antibody Development Agreement with the University of Pennsylvania
The collaboration aims for development of therapeutic monoclonal antibody candidates to target tumor hypoxia antigen.

Morphotek® Announces Collaborative Research Agreement with Ludwig Institute for Cancer Research
Collaboration to support proof-of-concept studies of novel disease targets and therapeutic antibodies.

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them
The patent relates to certain methods of enhancing the affinity of monoclonal antibodies (mAbs).

Morphotek Raises $40 Million to Advance Its Antibody Pipeline
The funds will be used primarily to further clinical development of the Company's lead therapeutic antibodies.

Morphotek® Announces Antibody Development Agreement with the University of Pennsylvania
The collaboration aims for development of therapeutic monoclonal antibody candidates to target tumor hypoxia antigen.

Morphotek® Announces Collaborative Research Agreement with Ludwig Institute for Cancer Research
Collaboration to support proof-of-concept studies of novel disease targets and therapeutic antibodies.

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them
The patent relates to certain methods of enhancing the affinity of monoclonal antibodies (mAbs).

Morphotek Raises $40 Million to Advance Its Antibody Pipeline
The funds will be used primarily to further clinical development of the Company's lead therapeutic antibodies.

Morphotek Divests Cell Evolution Service Business to Invitrogen
This divestment allows Morphotek to focus its business strategy on advancing its therapeutic antibody pipeline.

Morphotek Expands Oncology Pipeline with Product Candidate from NCI
Morphotek is applying its antibody technologies to develop and optimize antibodies to cancer-associated proteins.

Morphotek Announces Collaboration with the JWCI
Morphotek will apply its proprietary Human MORPHODOMA® antibody technology to develop antibodies.